Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
SLC2A2 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SLC2A1 Biologics Sequence Review Report 2026: Solute carrier family 2, facilitated glucose transporter member 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SLC2A1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC14 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 14 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC14 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC12 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 12 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC11 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 11 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC10 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 10 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC9 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 9 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC8 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 8 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC7 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 7 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC6 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC5 Biologics Sequence Review Report 2026: Sialic acid-binding Ig-like lectin 5 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
SIGLEC1 Biologics Sequence Review Report 2026: Sialoadhesin Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SIGLEC1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.